⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10290075 | 0.83 | — | — | |
| SCHEMBL14450775 | 0.81 | — | — | |
| SCHEMBL4935054 | 0.81 | — | — | |
| SCHEMBL9921940 | 0.81 | — | — | |
| SCHEMBL2608602 | 0.76 | — | — | |
| SCHEMBL7979840 | 0.72 | — | — | |
| SCHEMBL4197507 | 0.69 | — | — | |
| SCHEMBL15459135 | 0.67 | — | — | |
| SCHEMBL1058441 | 0.67 | — | — | |
| SCHEMBL21545414 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 393 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117105752-A | Preparation method of 1, 3-dibromo-2, 2-dimethoxypropane | 昊维联众生物医药技术(天津)有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-112236415-B | Process for the preparation of aminopyrimidines and intermediates therefor | 赛特凯恩蒂克公司 | 2023-11-14 | — | — | CN | claimed |
| CN-116986986-A | Synthesis method of 3-oxo-1-cyclobutanecarboxylic acid intermediate | 杭州国瑞生物科技有限公司 | 2023-11-03 | — | — | CN | claimed |
| CN-114213648-B | Hydrolyzable polymer and epoxy resin heat conducting material composition containing same | 安徽壹石通材料科学研究院有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-115611737-A | Method for preparing benzoic acid intermediate and intermediate thereof | 扬州奥锐特药业有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-115141858-A | Method for generating organic product by fixing carbon dioxide by using microorganisms | 江苏斯盖环保科技有限公司 | 2022-10-04 | — | — | CN | claimed |
| CN-111320535-B | Preparation method of 3- (benzyloxy) -1-cyclobutanone | 苏州楚凯药业有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-114213648-A | Hydrolyzable polymer and epoxy resin heat conduction material composition containing same | 安徽壹石通材料科学研究院有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-113248442-B | Preparation method of ergothioneine key intermediate | 泰州天鸿生化科技有限公司 | 2022-03-04 | — | — | CN | claimed |
| US-11142516-B2 | Process for the preparation of an amino-pyrimidine and intermediates thereof | CYTOKINETICS, INC. (US) | 2021-10-12 | — | — | US | claimed |
| CN-113248442-A | Preparation method of ergothioneine key intermediate | 泰州天鸿生化科技有限公司 | 2021-08-13 | — | — | CN | claimed |
| US-20210061786-A1 | PROCESS FOR THE PREPARATION OF AN AMINO-PYRIMIDINE AND INTERMEDIATES THEREOF | CYTOKINETICS, INC. (US) | 2021-03-04 | — | — | US | claimed |
| CN-112236415-A | Process for preparing aminopyrimidines and intermediates thereof | 赛特凯恩蒂克公司 | 2021-01-15 | — | — | CN | claimed |
| EP-3732166-A1 | PROCESS FOR THE PREPARATION OF AN AMINO-PYRIMIDINE AND INTERMEDIATES THEREOF | Cytokinetics, Incorporated (US) | 2020-11-04 | — | — | EP | claimed |
| CN-111320535-A | Preparation method of 3- (benzyloxy) -1-cyclobutanone | 苏州楚凯药业有限公司 | 2020-06-23 | — | — | CN | claimed |
| CN-107739328-B | Preparation method of key intermediate 1 for synthesizing barretinib | 海化生命(厦门)科技有限公司 | 2020-03-20 | — | — | CN | claimed |
| CN-107739328-A | For synthesizing preparation methods of the Ba Rui for the key intermediate 1 of Buddhist nun | 厦门海乐景生化有限公司 | 2018-02-27 | — | — | CN | claimed |
| CN-105037130-A | Synthesis method of 3-oxocyclobutanecarboxylic acid | SUZHOU VIVOTIDE BIOTECHNOLOGIES CO LTD | 2015-11-11 | — | — | CN | claimed |
| CN-104262121-A | Method for synthesizing 1,3-dibromo-2,2-dimethoxy propane | SUZHOU VIVOTIDE BIOTECHNOLOGIES CO LTD | 2015-01-07 | — | — | CN | claimed |
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260108512-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250388536-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4653436-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | GUANGZHOU YUFAN NANTU BIOTECHNOLOGIES CO., LTD (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250346612-A1 | INTRAMOLECULAR CYCLIZATION FOR GENERAL SYNTHESIS OF BICYCLIC ALKYL BIOISOSTERE BORONATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20250340552-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| EP-4573085-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS | Glenmark Pharmaceuticals Limited (IN) | 2025-06-25 | — | — | EP | disclosed |
| CN-114364670-B | Substituted benzyl-triazole compound for Cbl-b inhibition and further application thereof | 纽力克斯治疗公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | CONTINEUM THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250163074-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2025-05-22 | — | — | US | disclosed |
| US-20250163047-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-05-22 | — | — | US | disclosed |
| CN-120020133-A | Nitrogen-containing heterocyclic derivative and medical application thereof | 杭州百新生物医药科技有限公司 | 2025-05-20 | — | — | CN | disclosed |
| US-20250136590-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025076299-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119546587-A | Substituted pyridone compounds as CBL-B inhibitors | 格兰玛克制药有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-12234230-B2 | Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof | NURIX THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-119462360-A | Synthesis method of 3-oxo-1-cyclobutanecarboxylic acid | 中昊(大连)化工研究设计院有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| EP-4486444-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| US-12187709-B2 | Lactams as CBL-B inhibitors selective over C-CBL | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2024255762-A1 | CBL-B INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2024-12-19 | — | — | WO | disclosed |
| EP-4476219-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BeiGene, Ltd. (KY) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024245264-A1 | CBL-B INHIBITOR AND USE THEREOF | 海南先声再明医药股份有限公司 | 2024-12-05 | — | — | WO | disclosed |
| CN-118978523-A | Triazole heterocyclic compound | 上海信诺维生物医药有限公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-115141858-B | Method for producing organic product by using microorganism immobilized carbon dioxide | 江苏斯盖环保科技有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118871422-A | 3-Alkynyl carboxamides as AEP modulators | 豪夫迈·罗氏有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-12129262-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-10-29 | — | — | US | disclosed |
| US-20240317686-A1 | RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| CN-118696043-A | Heterocyclic compounds, compositions thereof and methods of treatment therewith | 百济神州有限公司 | 2024-09-24 | — | — | CN | disclosed |
| EP-4426691-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | Genentech, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | SIONNA THERAPEUTICS INC. | 2024-08-22 | — | — | US | disclosed |
| CN-118496070-A | Synthesis method of 3- (benzyloxy) -1-cyclobutanone | 武汉软件工程职业学院(武汉开放大学) | 2024-08-16 | — | — | CN | disclosed |
| WO-2024153240-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 珠海宇繁生物科技有限责任公司 | 2024-07-25 | — | — | WO | disclosed |
| US-20240228482-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4396179-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118201919-A | Indole compounds and methods of use | 健赞公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118201921-A | Lactams as CBL-B inhibitors selective for C-CBL | 基因泰克公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-114728938-B | Tetrahydroisoquinoline spiro compounds as PRMT5 inhibitors | 南京再明医药有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117903032-A | Preparation method of barytanib intermediate and method for preparing barytanib | 重庆博腾制药科技股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2024077236-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024077244-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024077244-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024077236-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024062363-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS CBL-B INHIBITORS | GLENMARK PHARMACEUTICALS LTD (IN) | 2024-03-28 | — | — | WO | disclosed |
| US-20240101535-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| WO-2024064745-A1 | SYNTHESIS OF RELDESEMTIV | CYTOKINETICS, INCORPORATED (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024064745-A1 | SYNTHESIS OF RELDESEMTIV | CYTOKINETICS, INCORPORATED (US) | 2024-03-28 | — | — | WO | disclosed |
| CN-114163323-B | Synthesis method of 3-oxo-cyclobutanecarboxylic acid | 大连双硼医药化工有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117751115-A | Compounds, compositions, and methods of treating cancer | 热点治疗公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024052739-A1 | METHOD FOR THE SYNTHESIS OF BENZODIOXEPINONE COMPOUNDS AND INTERMEDIATES THEREOF | AMBERNATH ORGANICS PVT. LTD. (IN) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024038378-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS | GLENMARK PHARMACEUTICALS LTD (IN) | 2024-02-22 | — | — | WO | disclosed |
| EP-4323358-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | Hotspot Therapeutics, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024020034-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4288429-A1 | LACTAMS AS CBL-B INHIBITORS | Genentech, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-117105752-A | Preparation method of 1, 3-dibromo-2, 2-dimethoxypropane | 昊维联众生物医药技术(天津)有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117105752-A | Preparation method of 1, 3-dibromo-2, 2-dimethoxypropane | 昊维联众生物医药技术(天津)有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117105752-A | Preparation method of 1, 3-dibromo-2, 2-dimethoxypropane | 昊维联众生物医药技术(天津)有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-112236415-B | Process for the preparation of aminopyrimidines and intermediates therefor | 赛特凯恩蒂克公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-4273129-A1 | RORgammaT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273129-A1 | RORgammaT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-116986986-A | Synthesis method of 3-oxo-1-cyclobutanecarboxylic acid intermediate | 杭州国瑞生物科技有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-116986986-A | Synthesis method of 3-oxo-1-cyclobutanecarboxylic acid intermediate | 杭州国瑞生物科技有限公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-4263525-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | Prelude Therapeutics, Incorporated (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-116940563-A | CDK inhibitors and their use as pharmaceuticals | 普莱鲁德疗法有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4261211-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| EP-4261211-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| CN-116888112-A | Lactams as CBL-B inhibitors | 基因泰克公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023194892-A1 | DI-SUBSTITUTED BENZODIOXEPINONES COMPOUND AS FRAGRANCES SOURCE AND IN PERFUME COMPOSITIONS | AMBERNATH ORGANICS PVT. LTD. (IN) | 2023-10-12 | — | — | WO | disclosed |
| CN-116783188-A | Dihydro-isoquinolone derivative and application thereof | 上海奕拓医药科技有限责任公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023165943-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023151640-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151641-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151636-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151642-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| EP-3661909-B1 | NOVEL SUBSTITUTED PHENYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3661909-B1 | NOVEL SUBSTITUTED PHENYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3694502-B1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3694502-B1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230212153-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | GENENTECH, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2023081853-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | GENENTECH, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20230079990-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| WO-2023034992-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023014907-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023014907-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| CN-115611737-A | Method for preparing benzoic acid intermediate and intermediate thereof | 扬州奥锐特药业有限公司 | 2023-01-17 | — | — | CN | disclosed |
| WO-2022257961-A1 | BENZOHETEROCYCLIC COMPOUND FOR TREATING EP2 AND EP4 RECEPTOR-MEDIATED DISEASES | 武汉人福创新药物研发中心有限公司 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022257961-A1 | BENZOHETEROCYCLIC COMPOUND FOR TREATING EP2 AND EP4 RECEPTOR-MEDIATED DISEASES | 武汉人福创新药物研发中心有限公司 | 2022-12-15 | — | — | WO | disclosed |
| CN-115448882-A | Benzoheterocyclic compounds useful for the treatment of EP2, EP4 receptor mediated diseases | 武汉人福创新药物研发中心有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-110248926-B | LSD1 inhibitor and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-113527081-B | Preparation method of 3-oxocyclobutanecarboxylic acid | 上海日异生物科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| WO-2022221704-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022221704-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| CN-115141858-A | Method for generating organic product by fixing carbon dioxide by using microorganisms | 江苏斯盖环保科技有限公司 | 2022-10-04 | — | — | CN | disclosed |
| US-11433053-B2 | LSD1 inhibitor and preparation method and application thereof | MEDSHINE DISCOVERY INC. (CN) | 2022-09-06 | — | — | US | disclosed |
| US-20220267345-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2022-08-25 | — | — | US | disclosed |
| WO-2022170218-A1 | INTRAMOLECULAR CYCLIZATION FOR GENERAL SYNTHESIS OF BICYCLIC ALKYL BIOISOSTERE BORONATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022169997-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| US-11401267-B2 | Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof | NURIX THERAPEUTICS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| CN-114728938-A | Tetrahydroisoquinoline spiro compounds as PRMT5 inhibitors | 江苏先声药业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022143771-A1 | RORγT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022143771-A1 | RORγT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2022-07-07 | — | — | WO | disclosed |
| CN-114685363-A | ROR gamma t regulator, preparation method and application thereof | 上海医药集团股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| WO-2022133215-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022122037-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | 上海奕拓医药科技有限责任公司 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122037-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | 上海奕拓医药科技有限责任公司 | 2022-06-16 | — | — | WO | disclosed |
| EP-3990117-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | Nurix Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-11319283-B2 | Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-05-03 | — | — | US | disclosed |
| CN-114364670-A | Substituted benzyl-triazoles for Cbl-b inhibition and further uses thereof | 纽力克斯治疗公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-111320535-B | Preparation method of 3- (benzyloxy) -1-cyclobutanone | 苏州楚凯药业有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-111320535-B | Preparation method of 3- (benzyloxy) -1-cyclobutanone | 苏州楚凯药业有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114213648-A | Hydrolyzable polymer and epoxy resin heat conduction material composition containing same | 安徽壹石通材料科学研究院有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| CN-114163323-A | Synthetic method of 3-oxocyclobutanecarboxylic acid | 大连双硼医药化工有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-113248442-B | Preparation method of ergothioneine key intermediate | 泰州天鸿生化科技有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-113248442-B | Preparation method of ergothioneine key intermediate | 泰州天鸿生化科技有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-11208407-B2 | Substituted phenyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11142516-B2 | Process for the preparation of an amino-pyrimidine and intermediates thereof | CYTOKINETICS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142516-B2 | Process for the preparation of an amino-pyrimidine and intermediates thereof | CYTOKINETICS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| CN-113248442-A | Preparation method of ergothioneine key intermediate | 泰州天鸿生化科技有限公司 | 2021-08-13 | — | — | CN | disclosed |
| CN-113248442-A | Preparation method of ergothioneine key intermediate | 泰州天鸿生化科技有限公司 | 2021-08-13 | — | — | CN | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3652157-B1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2021-05-05 | — | — | EP | disclosed |
| EP-3652157-B1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2021-05-05 | — | — | EP | disclosed |
| US-20210061786-A1 | PROCESS FOR THE PREPARATION OF AN AMINO-PYRIMIDINE AND INTERMEDIATES THEREOF | CYTOKINETICS, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210061786-A1 | PROCESS FOR THE PREPARATION OF AN AMINO-PYRIMIDINE AND INTERMEDIATES THEREOF | CYTOKINETICS, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210053961-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| CN-112236415-A | Process for preparing aminopyrimidines and intermediates thereof | 赛特凯恩蒂克公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2020264398-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-3735410-A1 | PICOLINAMIDE COMPOUNDS | Tempest Therapeutics, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| EP-3732166-A1 | PROCESS FOR THE PREPARATION OF AN AMINO-PYRIMIDINE AND INTERMEDIATES THEREOF | Cytokinetics, Incorporated (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200331864-A1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2020-10-22 | — | — | US | disclosed |
| US-20200277252-A1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3694502-A1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10738015-B2 | 1,3-diaza-spiro-[3.4]-octane derivatives | Grünenthal GmbH (DE) | 2020-08-11 | — | — | US | disclosed |
| US-20200216443-A1 | NOVEL SUBSTITUTED PHENYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-07-09 | — | — | US | disclosed |
| CN-111320535-A | Preparation method of 3- (benzyloxy) -1-cyclobutanone | 苏州楚凯药业有限公司 | 2020-06-23 | — | — | CN | disclosed |
| CN-111320535-A | Preparation method of 3- (benzyloxy) -1-cyclobutanone | 苏州楚凯药业有限公司 | 2020-06-23 | — | — | CN | disclosed |
| EP-3661909-A1 | NOVEL SUBSTITUTED PHENYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3652157-A1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | Grünenthal GmbH (DE) | 2020-05-20 | — | — | EP | disclosed |
| EP-3319962-B1 | ARYL SULTAM DERIVATIVES AS RORC MODULATORS | HOFFMANN LA ROCHE (CH) | 2020-05-13 | — | — | EP | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| CN-107739328-B | Preparation method of key intermediate 1 for synthesizing barretinib | 海化生命(厦门)科技有限公司 | 2020-03-20 | — | — | CN | disclosed |
| CN-107739328-B | Preparation method of key intermediate 1 for synthesizing barretinib | 海化生命(厦门)科技有限公司 | 2020-03-20 | — | — | CN | disclosed |
| EP-3068785-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-3068785-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-06-26 | — | — | EP | disclosed |
| WO-2019079614-A1 | PICOLINAMIDE COMPOUNDS | TEMPEST THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019074747-A1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019074747-A1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-04-18 | — | — | WO | disclosed |
| US-10259808-B2 | Aryl sultam derivatives as RORc modulators | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| WO-2019027855-A1 | NOVEL SUBSTITUTED PHENYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019027855-A1 | NOVEL SUBSTITUTED PHENYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019012037-A1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | Grünenthal GmbH (DE) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019012037-A1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | Grünenthal GmbH (DE) | 2019-01-17 | — | — | WO | disclosed |
| US-20190016685-A1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | Grünenthal GmbH (DE) | 2019-01-17 | — | — | US | disclosed |
| US-20180263996-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| EP-3319962-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2018-05-16 | — | — | EP | disclosed |
| US-20180105516-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| EP-2875021-B1 | BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | UNIV SAINT LOUIS (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-2168968-B1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| WO-2017005900-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-01-12 | — | — | WO | disclosed |
| WO-2017005668-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-01-12 | — | — | WO | disclosed |
| EP-3068785-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| CN-103717589-B | For treating or prevent the compound of respiratory syncytial virus disease | 弗·哈夫曼-拉罗切有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| WO-2016044770-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-9278965-B2 | Bridged and fused antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2016-02-18 | — | — | US | disclosed |
| US-9227991-B2 | Anti-tumor bivalent platinum complex and preparation method for complex and ligand of complex | SOUTHEAST UNIVERSITY (CN) | 2016-01-05 | — | — | US | disclosed |
| US-9227991-B2 | Anti-tumor bivalent platinum complex and preparation method for complex and ligand of complex | SOUTHEAST UNIVERSITY (CN) | 2016-01-05 | — | — | US | disclosed |
| US-9221838-B2 | Inhibitors of AKT activity | ALMAC DISCOVERY LIMITED (IE) | 2015-12-29 | — | — | US | disclosed |
| CN-105037130-A | Synthesis method of 3-oxocyclobutanecarboxylic acid | SUZHOU VIVOTIDE BIOTECHNOLOGIES CO LTD | 2015-11-11 | — | — | CN | disclosed |
| CN-105037130-A | Synthesis method of 3-oxocyclobutanecarboxylic acid | SUZHOU VIVOTIDE BIOTECHNOLOGIES CO LTD | 2015-11-11 | — | — | CN | disclosed |
| US-20150299237-A1 | ANTI-TUMOR BIVALENT PLATINUM COMPLEX AND PREPARATION METHOD FOR COMPLEX AND LIGAND OF COMPLEX | SOUTHEAST UNIVERSITY (CN) | 2015-10-22 | — | — | US | disclosed |
| US-20150299237-A1 | ANTI-TUMOR BIVALENT PLATINUM COMPLEX AND PREPARATION METHOD FOR COMPLEX AND LIGAND OF COMPLEX | SOUTHEAST UNIVERSITY (CN) | 2015-10-22 | — | — | US | disclosed |
| EP-2742039-B1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-9115127-B2 | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9085606-B2 | Beta amino acid derivatives as integrin antagonists | SAINT LOUIS UNIVERSITY (US) | 2015-07-21 | — | — | US | disclosed |
| EP-2389368-B1 | BRIDGED AND FUSED ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2015073763-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073763-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-8957089-B2 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-02-17 | — | — | US | disclosed |
| US-8957089-B2 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-02-17 | — | — | US | disclosed |
| US-8957089-B2 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-02-17 | — | — | US | disclosed |
| CN-104262121-A | Method for synthesizing 1,3-dibromo-2,2-dimethoxy propane | SUZHOU VIVOTIDE BIOTECHNOLOGIES CO LTD | 2015-01-07 | — | — | CN | disclosed |
| CN-104262121-A | Method for synthesizing 1,3-dibromo-2,2-dimethoxy propane | SUZHOU VIVOTIDE BIOTECHNOLOGIES CO LTD | 2015-01-07 | — | — | CN | disclosed |
| CN-104262121-A | Method for synthesizing 1,3-dibromo-2,2-dimethoxy propane | SUZHOU VIVOTIDE BIOTECHNOLOGIES CO LTD | 2015-01-07 | — | — | CN | disclosed |
| US-8921380-B2 | Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20140350044-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS, INC. | 2014-11-27 | — | — | US | disclosed |
| EP-2300422-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8871756-B2 | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease | HOFFMANN-LA ROCHE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2771322-A2 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2014-09-03 | — | — | EP | disclosed |
| EP-2516435-B1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LTD (GB) | 2014-08-06 | — | — | EP | disclosed |
| US-8772499-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2742039-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-8735405-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-8691804-B2 | Azetidines and cyclobutanes as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-04-08 | — | — | US | disclosed |
| US-8691804-B2 | Azetidines and cyclobutanes as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-04-08 | — | — | US | disclosed |
| US-20140080803-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8653268-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653100-B2 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653100-B2 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653100-B2 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20140038970-A1 | BRIDGED AND FUSED ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8642576-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642576-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2520577-B1 | Pyrazolo[1,5-a]pyrimidine compounds as cb1 receptor antagonists | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-20130225556-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130203749-A1 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203749-A1 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203749-A1 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN-LA ROCHE INC. | 2013-08-01 | — | — | US | disclosed |
| US-20130190496-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2013-07-25 | — | — | US | disclosed |
| EP-2611784-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | Amgen, Inc (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8455521-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455521-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455521-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130116243-A1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| WO-2013062964-A2 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-02 | — | — | WO | disclosed |
| US-8420629-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| WO-2013020993-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | WO | disclosed |
| US-8367826-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| EP-2520577-A1 | Pyrazolo[1,5-a]pyrimidine compounds as CB1 receptor antagonists | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| EP-2516435-A1 | INHIBITORS OF AKT ACTIVITY | Almac Discovery Limited (GB) | 2012-10-31 | — | — | EP | disclosed |
| EP-2271625-B1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO KG (DE) | 2012-09-12 | — | — | EP | disclosed |
| EP-2271625-B1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO KG (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | TANIMOTO KOICHI (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120196847-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-08-02 | — | — | US | disclosed |
| US-8188097-B2 | Pyrazolo[1,5-A]pyrimidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-8163759-B2 | Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-04-24 | — | — | US | disclosed |
| WO-2011077098-A9 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2012-04-19 | — | — | WO | disclosed |
| US-8158616-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120077979-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120077798-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-03-29 | — | — | US | disclosed |
| EP-1954668-B9 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2012018668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-8101613-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110312967-A1 | BRIDGED AND FUSED ANTIDIABETIC COMPOUNDS | SCHERING CORPORATION (US) | 2011-12-22 | — | — | US | disclosed |
| EP-1954668-B1 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2011077098-A1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott BmbH & Co. KG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott BmbH & Co. KG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott BmbH & Co. KG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2308879-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2305682-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2300422-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| EP-2288610-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | Incyte Corporation (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-2261216-A2 | Pyrazoles as glucokinase activators | F. Hoffmann-La Roche AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-7820662-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100234409-A1 | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2010-09-16 | — | — | US | disclosed |
| US-20100234409-A1 | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2010-09-16 | — | — | US | disclosed |
| US-20100234409-A1 | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2010-09-16 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-7754737-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754737-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754737-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-2168968-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | US | disclosed |
| WO-2009121872-A2 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009114512-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
| EP-1457488-B1 | Intermediates for use in the preparation of urea compounds having muscarinic receptor antagonist activity | THERAVANCE INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7553841-B2 | Amino cyclobutylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553841-B2 | Amino cyclobutylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553841-B2 | Amino cyclobutylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| EP-2046755-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. Hoffmann-Roche AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| EP-2035427-A2 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | TANABE SEIYAKU CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | VITAE PHARMACEUTICAL, INC (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | VITAE PHARMACEUTICAL, INC (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | VITAE PHARMACEUTICAL, INC (US) | 2009-01-15 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1617841-A4 | AMINO CYCLOBUTYLAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1954668-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1945220-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008012227-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-31 | — | — | WO | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
| WO-2008004698-A2 | PYRAZOLO [1, 5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-10 | — | — | WO | disclosed |
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070134729-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070134729-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-06-14 | — | — | US | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| WO-2007046548-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
| EP-1753740-A2 | AMINO CYCLOPENTYL HETEROCYCLIC AND CARBOCYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7179794-B2 | Multivalent macrolide antibiotics | THERAVANCE, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179794-B2 | Multivalent macrolide antibiotics | THERAVANCE, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| EP-1740591-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
| US-20060211722-A1 | Amino cyclobutylamide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2006-09-21 | — | — | US | disclosed |
| WO-2006042150-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1617841-A1 | AMINO CYCLOBUTYLAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co. Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2006001958-A2 | AMINO CYCLOPENTYL HETEROCYCLIC AND CARBOCYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005097800-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2004082682-A1 | AMINO CYCLOBUTYLAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO. INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| EP-0839798-A2 | Intermediates for preparating non-peptide retroviral protease inhibitors | ABBOTT LABORATORIES (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5670675-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1997-09-23 | — | — | US | disclosed |
| US-5545750-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS | ABBOTT LABORATORIES (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0609289-B1 | IMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | UPJOHN CO (US) | 1996-07-17 | — | — | EP | disclosed |
| EP-0681582-A1 | PYRAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-15 | — | — | EP | disclosed |
| US-5442062-A | Treating hypertension, congestive heart failure | THE UPJOHN COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| EP-0609289-A1 | IMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. | UPJOHN CO (US) | 1994-08-10 | — | — | EP | disclosed |
| WO-1994017069-A1 | PYRAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE UPJOHN COMPANY (US) | 1994-08-04 | — | — | WO | disclosed |
| US-5246931-A | Triazine-substituted cyclobutane derivatives; viricides; side effect reduction | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-09-21 | — | — | US | disclosed |
| EP-0540209-A1 | Imidazole derivatives and pharmaceutical compositions containing the same | THE UPJOHN COMPANY (US) | 1993-05-05 | — | — | EP | disclosed |
| WO-1993008193-A1 | IMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | THE UPJOHN COMPANY (US) | 1993-04-29 | — | — | WO | disclosed |
| US-5153352-A | Viricides and antitumor agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| US-5142056-A | Human immunodeficiency virus protease inhibitor | ABBOTT LABORATORIES (US) | 1992-08-25 | — | — | US | disclosed |
| EP-0402646-A1 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0366059-A2 | Carbocyclic nucleoside analogs | BRISTOL-MYERS SQUIBB COMPANY (US) | 1990-05-02 | — | — | EP | disclosed |
| US-4622380-A | Alkylidene bromo-substituted arylene acetal and/or ketal polymers | PPG INDUSTRIES, INC. (US) | 1986-11-11 | — | — | US | disclosed |
| US-4622380-A | Alkylidene bromo-substituted arylene acetal and/or ketal polymers | PPG INDUSTRIES, INC. (US) | 1986-11-11 | — | — | US | disclosed |